Premium
Open label evaluation of the novel antipsychotic compound BW234U in chronic schizophrenics
Author(s) -
Schwarcz Glenn,
Halaris Angelos,
Dren Anthony,
Manberg Paul
Publication year - 1985
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430050412
Subject(s) - schizophrenia (object oriented programming) , antipsychotic , open label , medicine , anesthesia , psychology , pharmacology , psychiatry , adverse effect
In a 28‐day open label study, 15 inpatients with chronic schizophrenia in relapse were treated with BW234U. Approximately half of the patients showed marked improvement. Four patients showed no change and three dropped out. Thought disturbance improved markedly. The compound was tolerated very well.